<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[18, 26] patients with mixed dyslipidaemia and metabolic syndrome.<br>[96, 102] patients with mixed dyslipidaemia and MetS.<br>[107, 127] patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200mg/dl<br>[137, 141] n = 30)<br>[154, 158] n = 30)<br>[168, 172] n = 30)<br>[178, 184] only patients with MetS were included<br></td>
<td width=33%>
[18, 26] patients with mixed dyslipidaemia and metabolic syndrome.<br>[62, 68] metabolic syndrome (MetS).<br>[96, 102] patients with mixed dyslipidaemia and MetS.<br>[107, 127] patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200mg/dl<br>[137, 141] n = 30)<br>[154, 158] n = 30)<br>[168, 172] n = 30)<br>[178, 184] only patients with MetS were included<br></td>
<td width=33%>
[18, 26] patients with mixed dyslipidaemia and metabolic syndrome.<br>[62, 68] metabolic syndrome (MetS).<br>[96, 102] patients with mixed dyslipidaemia and MetS.<br>[107, 142] patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200mg/dl to rosuvastatin monotherapy 40mg/day (R group, n = 30) or<br>[178, 201] only patients with MetS were included (24, 23 and 24 in the R, RF and R groups respectively).<br></td>
</tr>
